|
1
|
Gill E and Perks CM: Mini-review: Current
bladder cancer treatment-The need for improvement. Int J Mol Sci.
25:15572024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lopez-Beltran A, Cookson MS, Guercio BJ
and Cheng L: Advances in diagnosis and treatment of bladder cancer.
BMJ. 384:e0767432024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu L, Lin N, Ye Y, Zhou S, Xu Y, Chen J,
Zhuang W and Wang Q: Prognostic and chemotherapeutic response
prediction by proliferation essential gene signature: Investigating
POLE2 in bladder cancer progression and cisplatin resistance. J
Cancer. 15:1734–1749. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Richters A, Aben KKH and Kiemeney LALM:
The global burden of urinary bladder cancer: An update. World J
Urol. 38:1895–1904. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harsanyi S, Novakova ZV, Bevizova K,
Danisovic L and Ziaran S: Biomarkers of bladder cancer: Cell-free
DNA, epigenetic modifications and non-coding RNAs. Int J Mol Sci.
23:132062022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lenis AT, Lec PM, Chamie K and Mshs MD:
Bladder cancer: A review. JAMA. 324:1980–1991. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Castaneda PR, Theodorescu D, Rosser CJ and
Ahdoot M: Identifying novel biomarkers associated with bladder
cancer treatment outcomes. Front Oncol. 13:11142032023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hautmann RE, Volkmer BG and Gust K:
Quantification of the survival benefit of early versus deferred
cystectomy in high-risk non-muscle invasive bladder cancer (T1G3).
World J Urol. 27:347–351. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng L, Lopez-Beltran A and Bostwick DG:
Bladder pathology. John Wiley & Sons, Inc.; Hoboken, NJ: pp.
1–733. 2012
|
|
10
|
Soukup V, Babjuk M, Bellmunt J, Dalbagni
G, Giannarini G, Hakenberg OW, Herr H, Lechevallier E and Ribal MJ:
Follow-up after surgical treatment of bladder cancer: A critical
analysis of the literature. Eur Urol. 62:290–302. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Witjes JA, Bruins HM, Carrion A, Cathomas
R, Comperat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini
A, et al: European association of urology guidelines on
muscle-invasive and metastatic bladder cancer: Summary of the 2023
guidelines. Eur Urol. 85:17–31. 2024. View Article : Google Scholar
|
|
12
|
Dobruch J and Oszczudłowski M: Bladder
cancer: Current challenges and future directions. Medicina
(Kaunas). 57:7492021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goto K, Morimoto M, Osaki M, Tanio A,
Izutsu R, Fujiwara Y and Okada F: The impact of AMIGO2 on prognosis
and hepatic metastasis in gastric cancer patients. BMC Cancer.
22:2802022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tanio A, Saito H, Amisaki M, Hara K,
Sugezawa K, Uejima C, Tada Y, Kihara K, Yamamoto M, Nosaka K, et
al: AMIGO2 as a novel indicator of liver metastasis in patients
with colorectal cancer. Oncol Lett. 21:2782021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goto K, Osaki M, Izutsu R, Tanaka H,
Sasaki R, Tanio A, Satofuka H, Kazuki Y, Yamamoto M, Kugoh H, et
al: Establishment of an antibody specific for AMIGO2 improves
immunohistochemical evaluation of liver metastases and clinical
outcomes in patients with colorectal cancer. Diagn Pathol.
17:162022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iida Y, Sato S, Izutsu R, Seong HK, Okawa
M, Osaku D, Komatsu H, Osaki M, Taniguchi F and Okada F: AMIGO2
expression as a predictor of recurrence in cervical cancer with
intermediate risk. Mol Clin Oncol. 19:562023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iida Y, Osaki M, Sato S, Izutsu R, Seong
H, Komatsu H, Taniguchi F and Okada F: AMIGO2 is involved in the
spread of peritoneal metastasis in serous ovarian cancer via
promoting adhesion to the peritoneal mesothelial cells. Int J Clin
Oncol. 29:1354–1363. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han D, Xiong B, Zhang X, Chen C, Yao Z, Wu
H, Cao J, Li J, Li P, Wang Z and Tian J: Knockdown of AMIGO2
suppresses proliferation and migration through regulating PPAR-γ in
bladder cancer. Hereditas. 161:212024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
The Japanese Urothelial Association, The
Japanese Society of Pathology, Japan Radiological Society and
Japanese Society of Medical Oncology (eds), . The general rule for
clinical and pathological studies on renal pelvic, ureteral, and
bladder cancer. 2nd Edition. Igakutosho Shuppan; Tokyo: pp. 1–180.
2021
|
|
20
|
Tian Y, Ma Z, Chen Z, Li M, Wu Z, Hong M,
Wang H, Svatek R, Rodriguez R and Wang Z: Clinicopathological and
prognostic value of Ki-67 expression in bladder cancer: A
systematic review and meta-analysis. PLoS One. 11:e01588912016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Akgul M, MacLennan GT and Cheng L: The
applicability and utility of immunohistochemical biomarkers in
bladder pathology. Human Pathol. 98:32–55. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krabbe LM, Bagrodia A, Haddad AQ, Kapur P,
Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, et al:
Multi-institutional validation of the predictive value of Ki-67 in
patients with high grade urothelial carcinoma of the upper urinary
tract. J Urol. 193:1486–1493. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nováková ZV, Kuniaková M, Žiaran S and
Harsányi Š: Molecular biomarkers of bladder cancer: A mini-review.
Physiol Res. 72:S247–S256. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O'Sullivan P, Sharples K, Dalphin M,
Davidson P, Gilling P, Cambridge L, Harvey J, Toro T, Giles N,
Luxmanan C, et al: A multigene urine test for the detection and
stratification of bladder cancer in patients presenting with
hematuria. J Urol. 188:741–747. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sugeeta SS, Sharma A, Ng K, Nayak A and
Vasdev N: Biomarkers in bladder cancer surveillance. Front Surg.
8:7358682021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Flores Monar GV, Reynolds T, Gordon M,
Moon D and Moon C: Molecular markers for bladder cancer screening:
An insight into bladder cancer and FDA-approved biomarkers. Int J
Mol Sci. 24:143742023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pycha A, Lodde M, Comploj E, Negri G,
Egarter-Vigl E, Vittadello F, Lusuardi L, Palermo S and Mian C:
Intermediate-risk urothelial carcinoma: An unresolved problem?
Urology. 63:472–475. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wallace E, Higuchi R, Satya M, McCann L,
Sin MLY, Bridge JA, Wei H, Zhang J, Wong E, Hiar A, et al:
Development of a 90-minute integrated noninvasive urinary assay for
bladder cancer detection. J Urol. 199:655–662. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Henning GM, Barashi NS and Smith ZL:
Advances in biomarkers for detection, surveillance, and prognosis
of bladder cancer. Clin Genitouri Cancer. 19:194–198. 2021.
View Article : Google Scholar
|
|
30
|
Lokeshwar VB, Habuchi T, Grossman HB,
Murphy WM, Hautmann SH, Hemstreet GP III, Bono AV, Getzenberg RH,
Goebell P, Schmitz-Dräger BJ, et al: Bladder tumor markers beyond
cytology: International Consensus Panel on bladder tumor markers.
Urology. 66 (Suppl 1):35–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng L, MacLennan GT and Bostwick DG:
Urologic surgical pathology. Elsevier Inc.; Philadelphia, PA: pp.
1–944. 2019
|
|
32
|
Smith ZL and Guzzo TJ: Urinary markers for
bladder cancer. F1000Prime Rep. 5:212013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maas M, Todenhöfer T and Black PC: Urine
biomarkers in bladder cancer-current status and future
perspectives. Nat Rev Urol. 20:597–614. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Amin MB, Trpkov K, Lopez-Beltran A and
Grignon D; Members of the IIiDUPG, : Best practices recommendations
in the application of immunohistochemistry in the bladder lesions:
Report from the International Society of Urologic Pathology
consensus conference. Am J Surg Pathol. 38:e20–e34. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McKenney JK, Desai S, Cohen C and Amin MB:
Discriminatory immunohistochemical staining of urothelial carcinoma
in situ and non-neoplastic urothelium: An analysis of cytokeratin
20, p53, and CD44 antigens. Am J Surg Pathol. 25:1074–1078. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part A: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rao Q, Williamson SR, Lopez-Beltran A,
Montironi R, Huang W, Eble JN, Grignon DJ, Koch MO, Idrees MT,
Emerson RE, et al: Distinguishing primary adenocarcinoma of the
urinary bladder from secondary involvement by colorectal
adenocarcinoma: Extended immunohistochemical profiles emphasizing
novel markers. Mod Pathol. 26:725–732. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Margulis V, Shariat SF, Ashfaq R,
Sagalowsky AI and Lotan Y: Ki-67 is an independent predictor of
bladder cancer outcome in patients treated with radical cystectomy
for organ-confined disease. Clin Cancer Res. 12:7369–7373. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Izutsu R, Osaki M, Seong H, Ogata S, Sato
R, Hamada JI and Okada F: AMIGO2 enhances the invasive potential of
colorectal cancer by inducing EMT. Cancer Gene Ther. 31:1786–1795.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bajorin DF, Witjes JA, Gschwend JE,
Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat
SF, Park SH, et al: Adjuvant nivolumab versus placebo in
muscle-invasive urothelial carcinoma. N Engl J Med. 384:2102–2114.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schlüter C, Duchrow M, Wohlenberg C,
Becker MH, Key G, Flad HD and Gerdes J: The cell
proliferation-associated antigen of antibody Ki-67: A very large,
ubiquitous nuclear protein with numerous repeated elements,
representing a new kind of cell cycle-maintaining proteins. J Cell
Biol. 123:513–522. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shui R, Yu B, Bi R, Yang F and Yang W: An
interobserver reproducibility analysis of Ki67 visual assessment in
breast cancer. PLoS One. 10:e01251312015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wen S, Zhou W, Li CM, Hu J, Hu XM, Chen P,
Shao GL and Guo WH: Ki-67 as a prognostic marker in early-stage
nonsmall cell lung cancer in Asian patients: A meta-analysis of
published studies involving 32 studies. BMC Cancer. 15:5202015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gayed BA, Youssef RF, Bagrodia A, Darwish
OM, Kapur P, Sagalowsky A, Lotan Y and Margulis V: Ki67 is an
independent predictor of oncological outcomes in patients with
localized clear-cell renal cell carcinoma. BJU Int. 113:668–673.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Acikalin D, Oner U, Can C, Acikalin MF and
Colak E: Predictive value of maspin and Ki-67 expression in
transurethral resection specimens in patients with T1 bladder
cancer. Tumori. 98:344–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tanabe K, Yoshida S, Koga F, Inoue M,
Kobayashi S, Ishioka J, Tamura T, Sugawara E, Saito K, Akashi T, et
al: High Ki-67 expression predicts favorable survival in
muscle-invasive bladder cancer patients treated with
chemoradiation-based bladder-sparing protocol. Clin Genitourin
Cancer. 13:e243–e251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen JX, Deng N, Chen X, Chen LW, Qiu SP,
Li XF and Li JP: A novel molecular grading model: Combination of
Ki67 and VEGF in predicting tumor recurrence and progression in
non-invasive urothelial bladder cancer. Asian Pac J Cancer Prev.
13:2229–2234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Makboul R, Refaiy AE, Badary FA, Abdelkawi
IF, Merseburger AS and Mohammed RA: Expression of surviving in
squamous cell carcinoma and transitional cell carcinoma of the
urinary bladder: A comparative immunohistochemical study. Korean J
Urol. 56:31–40. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gontero P, Gillo A, Fiorito C, Oderda M,
Pacchioni D, Casetta G, Peraldo F, Zitella A, Tizzani A and Ricceri
F: Prognostic factors of ‘high-grade’ Ta bladder cancers according
to the WHO 2004 classification: Are these equivalent to ‘high-risk’
non-muscle-invasive bladder cancer? Urol Int. 92:136–142. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mallofré C, Castillo M, Morente V and Solé
M: Immunohistochemical expression of CK20, p53, and Ki-67 as
objective markers of urothelial dysplasia. Mod Pathol. 16:187–191.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang L, Feng C, Ding G, Ding Q, Zhou Z,
Jiang H and Wu Z: Ki67 and TP53 expressions predict recurrence of
non-muscle-invasive bladder cancer. Tumour Biol. 35:2989–2995.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bryan RT, Zeegers MP, James ND, Wallace DM
and Cheng KK: Biomarkers in bladder cancer. BJU Int. 105:608–613.
2010. View Article : Google Scholar : PubMed/NCBI
|
